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INTRODUCTION 
Kidneys and bones are the major metabolic buffer systems in our body 
that help us to maintain the internal milieu. Disease in one naturally is going to 
affect the other in long term. The association between the two has long been 
known but not brought into the limelight till the recent decades. This increase 
in the importance being given to the mineral abnormalities is due to its high 
association with the cardiovascular disease and death due to CVD. 
As the renal blood flow diminishes in CKD, so does the GFR. The 
minerals that need to be excreted normally get stagnated behind. Hence the 
parathyroids overwork to reduce some of the mineral load to the kidneys by 
depositing them on the tissues. They achieve it by mobilizing the calcium from 
the bones, form adducts with the excess phosphates and the products get 
deposited in the tissues.    
This compensatory mechanism becomes a disease when the deposition 
starts to affect the functionality of the tissues, just like what obesity does to the 
body. So an ideal approach is to help reducing the renal mineral load rather 
than suppressing the compensation. 
This study aims to contribute some data about the mineral abnormalities 
of CKD in the south Indian population where the data about the disease is 
insufficient. 
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AIMS & OBJECTIVES: 
1. To study the patterns of various mineral abnormalities in stage 3-5 Chronic 
Kidney Disease patients in south Indian population.  
2. To find out the difference in the pattern of abnormalities between diabetic and 
non-diabetic Chronic Kidney Disease 
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REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
CHRONIC KIDNEY DISEASE: 
“Chronic kidney disease (CKD) is defined as kidney damage or 
glomerular filtration rate (GFR) below 60 ml/min per 1.73 m
2
 for 3 months or 
more irrespective of the cause”. 
RISK FACTORS: 
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STAGES OF CKD: 
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MINERAL BONE DISEASE 
The metabolic abnormalities occurring in CKD begin early in the course 
of the disease. But the term Renal Osteodystrophy is not adequate to describe 
all the changes that occur in the body with Chronic Kidney Disease. It only 
describes the changes occurring in the bone. Those are – Osteitis fibrosa, 
Osteomalacia, Adynamic bone disease, Mild & Mixed type.  
 Hence the term CKD-Mineral Bone Disease (CKD- MBD) was coined 
in 2005 September by KDIGO (Kidney Disease Improving Global Outcomes). 
It defines CKD-MBD as a “systemic disorder of mineral and bone metabolism 
due to CKD, manifested by one or a combination of the following 
 Abnormal metabolism of calcium, phosphorus, PTH & Vitamin D . 
 Abnormalities in Bone turnover, bone mineralization, bone growth 
& strength.  
 Vascular or extra-skeletal calcification .” [ 1]  
In this spectrum, Osteitis Fibrosa and Adynamic bone disease often 
occur in those patients who are on Hemodialysis. Osteomalacia occurs in some 
ethnic groups like Indo-Asians. Other diseases occur in both dialytic and pre-
dialytic CKD patients almost in similar incidence. 
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CLASSIFICATION OF RENAL OSTEODYSTROPHY:  
Bone biopsy is the most accurate tool to assess the bone health status 
during CKD.  KDIGO
[1]
 has suggested that bone biopsies obtained from CKD 
patients should be analysed in terms of “Turnover, Mineralisation & Volume 
(TMV).”  
TURNOVER: 
It is the rate of formation as well as resorption of the bone. The most 
accurate measure of bone turnover is Double Tetracycline Labelling. Its main 
limitations are it cannot be performed in autopsy samples and the obtained 
values of normal bone formation rates are inconsistent with some discrepancies 
[2].
 
MINERALISATION: 
The amount of unmineralised osteoid that tells about the bone health 
status is measured by mineralization lag time or osteoid maturation time, which 
depends upon the thickness of the osteoid & the thickness between the 
Tetracycline Labels. 
VOLUME: 
The bone volume tells about the bone fragility. It can also be measured 
by Bone Mineral Density using Dual Energy X-ray Absorptiometry.  
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Renal osteodystrophy is different from other bone diseases in that, Bone 
volume/ Trabecular volume ratio is lower in those patients who are undergoing 
dialysis than non-dialytic patients
[3-10]
. Also in dialytic patients with secondary 
hyperparathyroidism, cortical bone volume is low but the cancellous bone 
volume is high which is in contrary to osteoporosis where both volumes are 
decreased 
[11].
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PICTURE: Prevalence of various types of Renal osteodystrophy by bone 
biopsy in various CKD populations 
                OM= Osteomalacia  
                AD= Adynamic Bone Disease  
                OF= Osteitis Fibrosa  
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Based on the TMV parameters, Renal osteodystrophy is classified as 
Osteitis Fibrosa, Adynamic bone disease, Osteomalacia & Mixed and Mild 
types. 
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OSTEITIS FIBROSA: 
“Increased bone turnover due to Hyperparathyroidism & Hypocalcemia, 
leading to an increased osteoclast and osteoblast activity along with 
Peritrabecular Fibrosis.” This condition has normal or increased bone mass, 
increased osteoid volume & decreased secondary mineralization. 
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ADYNAMIC BONE DISEASE: 
“Abnormally low bone turnover occurring due to iPTH lower than 
normal and hypercalcemia.” This condition has low bone volume and high 
secondary mineralization.  
 
OSTEOMALACIA: 
“Defective mineralization of the newly formed osteoid.” It is essentially 
a low bone turnover state due to deficiency of vitamin-D. This condition has 
normal bone mass but abnormal mineralization. 
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PATHOGENESIS: 
 
PICTURE: Progression of CKD and the role of mineral metabolism 
abnormalities and bone pathology.  
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CALCIUM METABOLISM: 
During the early stages of CKD, there is a fall in the serum total calcium 
levels due to fall in the production of renal 1,25-0H Vitamin D, phosphate 
retention, reduced GI absorption of calcium. Persistently low level of unbound 
serum calcium is the potent stimulator for PTH secretion. Hence secondary 
Hyperparathyroidism occurs & tends to maintain the serum calcium levels, by 
replacing it from the bones. 
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PHOSPHATE METABOLISM: 
Till stage 4 CKD, the phosphate retention that occurs is not apparent. 
This is due to increased circulating levels of Fibroblast Growth Factor 23 
(FGF-23) as well as compensatory increase in PTH levels which maintains the 
serum phosphate level by increased phosphate excretion in urine 
[12].
 After that 
the ability to excrete phosphate decreases.   This hyperphosphatemia leads to 
decrease in Vitamin D level by inhibiting the renal enzyme 1-alpha-
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hydroxylase 
[13]
 and also worsens the hyperparathyroidism by inducing PTH 
resistance in bone. Phosphate is also an independent factor in affecting PTH 
secretion 
[14,15]
 and growth 
[16,17].
 
 
 Page | 18  
 
 
 
 
 
 Page | 19  
 
This vicious cycle of hypocalcemia, hyperparathyroidism, 
hyperphosphatemia and again hyperparathyroidism goes on till structural and 
functional abnormalities occur in parathyroid gland or the bone pool of calcium 
is exhausted. By this time extra skeletal calcification would have progressed to 
a severe extent. This combination of extra skeletal abnormalities and skeletal 
abnormalities lead to an impaired quality of life and mortality occurs due to 
cardiovascular disease. 
So appropriate measures have to be taken at each stage of CKD to arrest 
the progression of MBD and hence provide a good quality of life.   
VITAMIN-D METABOLISM: 
In CKD, the delivery of 25-OH vitamin D to the site of 1-alpha-
hydroxylase in the Proximal Convoluted Tubule is decreased leading to 
decreased production of 1,25 –OH vitamin D. Also the activity of 1-alpha-
hydroxylase is already suppressed in CKD due to hyperphosphatemia that 
induces the suppressor namely FGF-23. And circulating-PTH fragments 
directly inhibit calcitriol production.  
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The resultant deficiency of vitamin D leads to increased proliferation of 
parathyroid cells, increased set-point of calcium regulated PTH secretion, 
skeletal resistance to PTH and ultimately contributes to the 
hyperparathyroidism. 
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METABOLISM OF PARATHORMONE: 
Parathormone directly acts on bones and kidneys. In Proximal 
convoluted tubule, it inhibits phosphate transport whereas in distal convoluted 
tubule, it stimulates calcium reabsorption. 
Parathormone is a single peptide chain protein that has 84 amino acids 
[19].
 The N-terminal 1-34 amino acids are essentially conserved between 
numerous species and it is the necessary part needed for bioactivity of PTH. 
Proteolysis occurs in kidneys and liver.  
The N-terminal 7-84 amino acid truncated PTH has actions opposite to 
that of PTH. In fact it has hypocalcemic actions. The concentration of N-
terminal truncated 7-84 amino acid PTH is increased in CKD. It also interferes 
with the lab assay particularly the second generation assay leading to an 
interpretation of high PTH level. 
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The active form of PTH is 1-84 amino acid part. It exerts its action via 
the N-terminal 1-34 amino acids. But the circulating half-life of the bioactive 
PTH is 2-4 minutes. So at any time the circulating PTH consists of 1-84 amino 
acid part 5-30%, C-terminal fragments 70-95%, N-terminal fragments small 
percentage. 
PTH assays differ in detecting the PTH fragments thereby over and 
under estimating the true bioactive PTH level.  
First generation PTH assays detected only the C- or N- terminal 
fragments.  
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Second generation assay, the so called intact PTH (iPTH) assay, is 
actually a two-site sandwich immunoradiometric assay. It targets two regions 
of amino acids in the same peptide chain ie., anywhere in the N-terminal 1-37 
amino acids & C-terminal 38-84 amino acids. This method also detects the C-
terminal 7-84 fragments, which are a mixture of four types of PTH fragments 
that are similar in size to the 7-84 PTH 
[21].
 Half of what iPTH assay measures 
is the truncated 7-84 PTH. So it overestimates the bioactive PTH. Hence in 
CKD, despite a high iPTH level, there is a relative tissue level 
hypoparathyroidism 
[22,23].
 
Third generation assay, termed as Bio-Intact PTH assay, measures the 1-
84 fragment PTH using extreme N-terminal epitopes. But it is still under 
research. It is not commercially available. One study reported that 1-84 PTH / 
large C-PTH ratio is a better predictor of the bioactive PTH than iPTH 
[24].
 
In CKD, in bones there develops a resistance to the calcemic actions of 
PTH 
[18].
 This resistance is due to decreased calcitriol levels, phosphate 
retention, N-terminal truncated PTH fragments which have antagonistic actions 
to PTH 
[25,26].
 Hence for mobilizing the bone calcium, parathyroid gland over 
secretes PTH. The abnormalities that occur within the parathyroid gland are 
gland hyperplasia, reduced calcium receptors & decreased expression of 
vitamin D receptors. 
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LOW TURNOVER BONE DISEASE: 
More than 40% of stage 5 CKD patients have Adynamic bone disease. 
Initially the parathyroid glands over secrete to compensate for the metabolic 
abnormalities. Eventually it is burnt out. FGF-23 suppresses the PTH secretion 
[27].
 Adynamic bone disease occurs because of a very low iPTH which is less 
than 100pg/ml that decreases both osteoblast and osteoclast activities. Bone 
specific Alkaline Phosphatase levels fall in Adynamic bone disease.  
It is a low turnover, normal mineralization state of bone with a low bone 
volume. In CKD, Adynamic bones have twice the incidence of fracture as 
compared with high turnover bone states. “It is also highly associated with 
cardiovascular calcification and mortality 
[28-30].”
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If the Adynamic bone disease patients are given calcium supplements 
and bisphosphonates to protect the existing bone volume, they may land up in 
hypercalcemia and hyperphosphatemia, worsening the pre-existing extra-
skeletal calcification. 
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CLINICAL FEATURES: 
Mineral Bone Disease is clinically silent until very late in the course of 
the disease. The clinical features are non-specific and they appear relatively 
later than the biochemical or radiographic changes. They are non-specific aches 
in lower back, hips and legs that increase on weight bearing, gradual onset 
muscle weakness, bone pains that are deep dull aching pains that cannot be 
often localized by the patient, fractures occurring to trivial injuries.  
Osteosclerosis of the vertebral column appears as a prominence of the 
sub-end plate zones and radiolucency of the vertebral body. It is classically 
known as “Rugger-Jersey Spine” in x-ray as shown in the picture below. 
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Brown tumors, which are not actually tumors but look like one in an x-
ray due to its radiolucency. It occurs due to high osteoclast activity. It will lead 
to fractures more commonly in the axial skeleton than in the appendicular 
skeleton, leading to kyphoscoliosis and chest wall deformities. 
In children bone deformities & growth arrest occur. 
 
PICTURE: Brown tumor of hand  
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Extra skeletal calcifications which are due to calcium phosphate product 
occur in various locations like blood vessels, heart valves, around the joints etc. 
One such feature is Calciphylaxis otherwise known as Calcific uremic 
arteriopathy, a rare presentation in which Tunica media of cutaneous arteries 
are calcified.   
DIAGNOSIS: 
The prevalence of various histologic types of renal osteodystrophy 
among those who have symptoms like bone pain, myopathy etc,  and those who 
don’t have symptoms, in CKD patients on Hemodialysis is almost similar [4-10, 
31].
          
.
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Low turnover bone disease has high fracture rates than high turnover 
bone disease (0.2 / yr vs 0.1 / yr) 
[32-34].
 Also adynamic bone disease predicts 
coronary artery calcification 
[35-37].
 Hence it is necessary to know the type of 
renal osteodystrophy of the patient. 
Bone mineral density measurements using Dual Energy X-ray 
Absorptiometry (DEXA) scan does not predict the fracture risk 
[32, 34, 38].
 BMD 
is measured in g/cm
2
 and it does not say about the bone depth as well as how 
much is the cortical bone and trabecular bone since both of them behave 
differently in CKD. It poses an even more challenge in pediatric age group. 
Hence BMD cannot differentiate the types of Renal oteodystrophy 
[34, 39-43].
 
Studies comparing bone formation in bone biopsy vs serum bio-markers 
of bone formation 
[44-56]
 show that there is some correlation between Bone 
specific Alkaline Phosphatase and bone formation rate than PTH which was 
once thought to reflect bone turnover. PTH is a marker of parathyroid activity 
rather than bone turnover 
[76].
 And also BAP might predict high or low bone 
turnover 
[51, 57, 58].
 Other markers like deoxypyridinoline, Tumor necrosis factor- 
alpha, osteocalcin, osteoprotegrin have insufficient evidence to be used as 
markers.   
All these facts make Bone biopsy as the gold standard tool in assessing 
bone health in CKD. It is invasive and also needs special equipments and 
expertise to carry out. Bone biopsy is also not possible in all clinical settings. 
This fact consolidates “but not limits the use of bone biopsy to reasonable 
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situations like unexplained fractures, persistent bone pain, unexplained 
hypercalcemia or hypophosphatemia, suspected aluminium toxicity in a 
dialysis patient, provided biopsy is done prior to starting bisphosphonate 
therapy.” 
Lateral abdominal plain X-ray and echocardiography are sufficient for 
assessing vascular and valvular calcification. 
 
INTERVENTIONS: 
Mineral bone disease is a spectrum of disorders rather than a single 
disease. Proper screening with the available tools beginning earlier in the 
course of CKD and initiating appropriate measures at the right time is the best 
method in preventing its occurrence and improving the quality of life thereby 
reducing morbidity and mortality. 
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In earlier stages of CKD, when there is a high bone turnover, PTH 
suppression is the main strategy because if once parathyroid gland hyperplasia 
occurs, then the tissue won’t involute and so bringing the PTH to normal levels 
will be very difficult 
[59].
  PTH levels should be kept within 3 – 9 times the 
normal limit since the extremes of values are associated with high morbidity 
and mortality. The recent KDIGO guidelines advise the Target range for iPTH 
to be 120-540 pg/ml.  
Prevent hyperphosphatemia since phosphate is a direct cause for 
secondary hyperparathyroidism 
[62, 63],
 bone abnormalities 
[64],
 calcitriol 
deficiency 
[65],
 extra skeletal calcification 
[66]
 and parathyroid gland 
proliferation 
[63, 67, 68].
 And it also reduces the secondary hyperparathyroidism 
and the Cardiovascular disease risk 
[60, 61].
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Phosphate reduction is achieved by various methods like dietary 
phosphate restriction and various phosphate binders. Phosphate binders are 
associated with a lot of adverse effects like hypercalcemia, aluminium toxicity, 
GI intolerance etc. It also increases the pill load and cost of the treatment.  
Studies have not established causality for phosphates in cardiovascular 
mortality 
[69] 
although there is an association between the two. Hence it is 
generally accepted that phosphate lowering is tailored to individual patients. 
Hypocalcemia should be treated since it is a stimulus for PTH secretion but 
routinely supplementing calcium salts will not lower the iPTH levels 
[70].
 Of the 
phosphate binders studied, sevelamer hydrochloride is found to stop the 
progression of vascular calcification 
[71].
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Supplementing vitamin D will reduce the PTH level. But it should not 
be started without knowing if the patient is in hyperparathyroidism because it 
may lead to hypercalcemia and hyperphosphatemia.  
Cinacalcet is a calcimietic agent. It acts on calcium receptor and 
increases its sensitivity. It reduces PTH levels in dialysis patients. But it leads 
to phosphate retention in non-dialytic patients. When added to conventional 
treatment, patients having iPTH levels >300pg/ml will achieve greater 
suppression of PTH 
[75]. 
Newer calcitriol analogues namely 22-oxacalcitriol 
(OCT), 1α-hydroxyvitamin D2, and 19-nor-1α,25- dihydroxyvitamin D2 
(paricalcitol) suppress PTH with low calcemic effects 
[72-74].
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If severe hypercalcemia occurs in the presence of extreme elevations of 
iPTH >1000pg/ml and elevated BAP, it indicates parathyroid gland 
hyperplasia. Such patients will not respond to any form of drug therapy. They 
are the candidates for parathyroidectomy. They will be benefitted more if they 
undergo renal transplant. 
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Before undergoing parathyroidectomy rule out aluminium toxicity 
because such patients will land up in osteomalacia after surgery. Occurrence of 
calciphylaxis is an emergency indication for parathyroidectomy. 
Treatment of Adyanmic bone disease involves bringing the PTH levels 
back to normal without causing hyperparathyroidism. It includes reducing 
vitamin D supplements, avoiding hypercalcemia and hyperphosphatemia and 
recombinant Parathormone supplement if the patient is parathyroidectomised. 
Adynamic bone disease is highly refractory to treatment.  
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MATERIALS & METHODS 
STUDY DESIGN: 
Cross – sectional study 
STUDY PERIOD: 
January 2016 to June 2016 
STUDY AREA: 
Govt. Kilpauk Medical College, Chennai, Tamil nadu. 
STUDY POPULATION: 
CKD patients attending the Nephrology department, Govt 
kilpauk Medical College, Chennai. 
INCLUSION CRITERIA: 
Stage 3-5 predialytic CKD patients. 
EXCLUSION CRITERIA: 
Patients  already on dialysis and transplant patients. 
Patients with known parathyroid abnormalities. 
Patients who are taking NSAIDS, Anti-epileptics. 
Known liver diseases, rickets, osteomalacia patients 
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After obtaining consent from the patient, with aseptic precautions, about 
8 ml of venous blood is obtained from the median cubital vein without 
applying tourniquet, at 10 am to 12 pm. Blood collection is done like this 
because factors like central vein blood or peripheral blood, winter season or 
summer season, nocturnal or daylight, will affect the PTH concentration 
[77].
 3 
ml of blood is collected in K2-EDTA tube for separating plasma. 5 ml of blood 
is collected in Red topped Standard serum separating tube. After allowing the 
sample  to clot at room temperature for about one hour, samples are centrifuged 
and serum & plasma are separately aspirated using Pasteur pipettes. Samples 
are separately stored in 1 ml eppendorf tubes.  
Thus 4 alliquots are allotted for every patient. Serum and plasma 
samples are stored at -20
o 
C ice lined refrigerator. All samples are analysed 
within 3 months of collection. Plasma samples are analyzed for 25-OH Vitamin 
D and iPTH. Serum samples are analyzed for all other biochemical parameters.  
VITAMIN D: 
The active form of vitamin D is 1,25-OH vitamin D. But its circulatory 
half life is very low. Hence its metabolite 25-OH vitamin D is used to is used to 
measure the overall vitamin d status of the body, as it is the major storage form 
and its half life is 2-3 weeks. The kit used in this study is ms-05894913 190 by 
Roche diagnostics and was carried out on cobas e411 ECLIA analyzer. The 
stability of vitamin d in K2 EDTA plasma at -20
o
C is for 24 weeks. The 
measuring range is 3.00-70.0 ng/ml. The shelf life of unopened kit is upto 
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expiry date; opened and at 2-8
o
C is 8 weeks; On cobas e 411 analyzer is 3 
weeks.  
PARATHORMONE: 
The iPTH assay is carried out using the 2 site Electro Chemi 
Luminescence Immuno Assay. The kit used is ms-11972103122 on cobas e 411 
analyzer. The antibodies used in this test reacts at N-terminal 1-37 amino acids 
at 26-32 amino acid epitope and C-terminal 38-84 amino acids at 37-42 amino 
acid epitope. Measuring range is 1.20-5000pg/ml. The stability of PTH at -
20
o
C in plasma is for 6 months. This method has no cross reactivity with PTH 
1-37, PTHrP 1-86. The shelf life of unopened kit at 2-8
o
C is up to expiry date; 
opened and at 2-8
o
C is 12 weeks; on the analyzer is 8 weeks. 
BONE SPECIFIC ALKALINE PHOSHATASE: 
This assay was carried out by ELISA in microtitre strip method, with 
Microvue BAP ELISA kit-046001 from Quidel Corporation, San Diego, USA 
in Robonik readwell Touch ELISA plate analyser and Robonik washwell plate 
ELISA washer. The stability of the enzyme in serum is 5 days at 2-8
o
C; twelve 
months at -20
o
C; 36 months at -80
o
C.   
CALCIUM: 
This assay is done using the Calcium Gen 2 kit- 05061482 190from 
Roche, and analysed using cobas c 311 analyzer. The assay is based on the 
change in absorbance of 376nm wavelength light that is measured 
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photometrically. Stability of the serum calcium at -20
o
C is 8 months. The range 
of measurement of this method is 0.8-20.1 mg/dl. The measured parameter is 
the serum total calcium. It is corrected according to the serum albumin to 
calculate corrected calcium. 
PHOSPHORUS: 
This assay is done using Inorgnic Phosphate ver.2 kit- 03183793 122 
from Roche, on cobas c 311 analyzer. The assay is based on Molybdate UV 
principle, which measures the change in absorbance of the Ammonium 
phosphomolybdate which subsequently reduces to molybdenum. The stability 
of the phosphate ions in serum stored at -20
 o
C is 1 year. 
UREA: 
This assay is done using the UreaL kit- 04460715 190 from Roche, on 
cobas c 311 analyzer. The assay is based on the Kinetic test principle with 
Urease and Glutamate dehydrogenase enzymes. The resulting NADH 
concentration is measured photometrically and is directly proportionate to the 
concentration of urea. The stability of urea in serum stored at -20
 o
C is 1 year. 
CREATININE: 
This assay is done using the CREJ2 kit- 04810716 190 from Roche, on 
cobas c 311 analyzer. The assay is based on kinetic colorimetric principle using 
Jaffe’s method that forms a Yellow orange complex that is measured 
photometrically. The serum stability for creatinine at -20
 o
C is 3 months, the 
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shortest of all parameters in our study. Hence all analyses are completed within 
three months of sample collection. Patients are staged according to eGFR 
calculation using CKD-EPI equation. 
MAGNESIUM: 
This assay is done using Robonik Prietest Touch photocolorimeter 
machine based on Xylidyl blue method. The normal range by this method is 1.6 
to 2.8 mg/dl. 
SYMPTOMS: 
Questionnaire regarding symptoms of CKD-MBD is given to all the 
patients in our study. “Bone pain, proximal muscle weakness and fragile 
fractures” are asked about. Those who are having one or more of the symptoms 
are considered as symptomatic.  
Ophthalmic fundus examination is carried out in feasible patients who 
don’t have cataract or other ocular abnormalities.   
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STATISTICAL ANALYSIS: 
The data were analysis using SPSS (Statistical Package for Social 
Science) Ver 16.01. The data collected were scored and analyzed & categorical 
variables were presented as frequency and percentages. Student t-test was used 
for testing the significance of all the variables mean and standard deviation in 
groups. Chi-square test was used to compare proportions. Pearson Correlation 
test were used to find out the relationship between the variables. All the 
statistical results were considered significant at P value ≤ 0.05. 
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OBSERVATION & 
RESULTS 
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OBSERVATION & RESULTS 
Prevalence of various abnormalities in stages 3-5 of CKD observed are 
listed below. 
CALCIUM: 
The serum total calcium observed is corrected for serum albumin. The 
Prevalence of calcium abnormalities is as follows. 
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In our study we had 25, 34 & 24 stage3, 4 & 5 CKD patients 
respectively. The normal value of serum calcium is 8.6-10 mg/dl. 
 The prevalence of hypocalcemia in stage 3, 4 & 5 are 12%, 11.6% & 
37.5% respectively. 
The prevalence of normocalcemia in stage 3, 4 & 5 CKD are 76%, 
79.41% & 58.33% respectively. 
The prevalence of hypercalcemia in stage 3, 4 & 5 CKD are 12%, 8.82% 
& 4.17% respectively. 
The overall prevalence of hypocalcemia, normocalcemia & 
hypercalcemia in stage 3-5 CKD is 19.28%, 72.29% & 8.43% respectively. 
This prevalence is not statistically significant as per our study. 
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PARATHORMONE: 
Prevalence of iPTH abnormalities in stage 3-5 CKD is as follows. 
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The prevalence of hypoparathyroidism in stage 3, 4 & 5 are 12%, 2.94% 
& 4.17% respectively. 
The prevalence of normoparathyroidism in stage 3, 4 & 5 CKD are 36%, 
38.24% & 8.33% respectively. 
The prevalence of hyperparathyroidism in stage 3, 4 & 5 CKD are 52%, 
58.82% & 87.5% respectively. 
The overall prevalence of hypoparathyroidism, normoparathyroidism & 
hyperparathyroidism in stage 3-5 CKD is 6.02%, 28.92% & 65.06% 
respectively. 
This prevalence is statistically significant as per our study. 
 
VITAMIN D: 
Prevalence of Vitamin D abnormalities in stage 3-5 CKD is as follows. 
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The prevalence of Vitamin D deficiency in stage 3, 4 & 5 are 4%, 
20.59% & 0% respectively. 
The prevalence of no deficiency of Vitamin D in stage 3, 4 & 5 CKD are 
96%, 79.41% & 100% respectively. 
The overall prevalence of vitamin D deficiency and no deficiency in 
stage 3-5 CKD is 9.64% & 90.36% respectively. 
This prevalence is statistically significant as per our study. 
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MAGNESIUM: 
Prevalence of Magnesium abnormalities in stages 3-5 CKD is as 
follows. 
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The prevalence of hypomagnesemia in stage 3, 4 & 5 are 16%, 28 % & 
56% respectively. 
The prevalence of normomagnesemia in stage 3, 4 & 5 CKD are 
17.65%, 47.06% & 35.29% respectively. 
The prevalence of hypermagnesemia in stage 3, 4 & 5 CKD are 20.83%, 
41.67% & 37.50% respectively. 
The overall prevalence of hypoagnesemia, normoagnesemia & 
hypermagnesemia in stage 3-5 CKD is 18.07%, 39.76% & 42.17% 
respectively. 
This prevalence is statistically not significant as per our study. 
PHOSPHORUS: 
Prevalence of phosphorus abnormalities in stage 3-5 CKD is as follows. 
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The prevalence of hypophosphhatemia in stage 3, 4 & 5 are 20%, 8.82% 
& 0% respectively. 
The prevalence of normophosphatemia in stage 3, 4 & 5 CKD are 76%, 
73.53% & 50% respectively. 
The prevalence of hyperphosphatemia in stage 3, 4 & 5 CKD are 4%, 
17.65% & 50% respectively. 
The overall prevalence of hypophosphatemia, normophosphatemia & 
hyperphosphatemia in stage 3-5 CKD is 9.64%, 67.47% & 22.89% 
respectively. 
This prevalence is statistically significant as per our study. 
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BONE SPECIFIC ALKALINE PHOSPHATASE: 
Prevalence of abnormal BAP in stages 3-5 of CKD is as follows. 
 
 
The prevalence of low BAP in stage 3, 4 & 5 are 8%, 0% & 4.17% 
respectively. 
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The prevalence of normal BAP in stage 3, 4 & 5 CKD are 84%, 70.59% 
& 70.83% respectively. 
The prevalence of high BAP in stage 3, 4 & 5 CKD are 8%, 29.41% & 
25% respectively. 
The overall prevalence of low BAP, normal BAP & high BAP in stage 
3-5 CKD is 3.61%, 74.70% & 21.69% respectively. 
This prevalence is statistically not significant as per our study. 
CALCIUM: NON-DIABETIC VS DIABETIC: 
Prevalence of calcium abnormalities in Diabetic and Non-diabetic CKD 
is as follows. 
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The prevalence of hypocalcemia in non-diabetic and diabetic CKD stage 
3-5 is 21.74% & 16.22% respectively. 
The prevalence of normoocalcemia in non-diabetic and diabetic CKD 
stage 3-5 is 65.22% & 81.08% respectively. 
The prevalence of hypercalcemia in non-diabetic and diabetic CKD 
stage 3-5 is 13.04% & 2.72% respectively. 
The difference in calcium abnormalities in stage 3-5 diabetic and non-
diabetic CKD is statistically not significant.  
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PTH: NON-DIABETIC VS DIABETIC: 
Prevalence of iPTH abnormalities in Diabetic and non-diabetic CKD is 
as follows. 
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The prevalence of hypoparathyroidism in non-diabetic and diabetic 
CKD stage 3-5 is 6.52% & 5.41% respectively. 
The prevalence of normoparathyroidism in non-diabetic and diabetic 
CKD stage 3-5 is 21.74% & 51.85% respectively. 
The prevalence of hyperparathyroidism in non-diabetic and diabetic 
CKD stage 3-5 is 71.74% & 56.76% respectively. 
The difference in parathyroid abnormalities in stage 3-5 diabetic and 
non-diabetic CKD is statistically not significant.  
VITAMIN D: NON-DIABETIC VS DIABETIC: 
Prevalence of Vitamin D abnormalities in Diabetic and Non-Diabetic 
CKD is as follows. 
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The prevalence of low vitamin D in non-diabetic and diabetic CKD 
stage 3-5 is 13.04% & 13.51% respectively. 
The prevalence of normal vitamin D in non-diabetic and diabetic CKD 
stage 3-5 is 86.96% & 86.49% respectively. 
The difference in vitamin D abnormalities in stage 3-5 diabetic and non-
diabetic CKD is statistically not significant.  
 
MAGNESIUM : NON-DIABETIC VS DIABETIC: 
Prevalence of Magnesium abnormalities in Diabetic and Non-Diabetic 
CKD is as follows. 
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The prevalence of hypomagnesemia in non-diabetic and diabetic CKD 
stage 3-5 is 17.39% & 18.92% respectively. 
The prevalence of normomagnesemia in non-diabetic and diabetic CKD 
stage 3-5 is 41.30% & 37.84% respectively. 
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The prevalence of hypermagnesemia in non-diabetic and diabetic CKD 
stage 3-5 is 41.30% & 43.24% respectively. 
The difference in magnesium abnormalities in stage 3-5 diabetic and 
non-diabetic CKD is statistically not significant.  
PHOSPHORUS: NON-DIABETIC VS DIABETIC: 
Prevalence of phosphorus abnormalities in Diabetic and Non-Diabetic 
CKD is as follows. 
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The prevalence of hypophosphatemia in non-diabetic and diabetic CKD 
stage 3-5 is 13.04% & 5.49% respectively. 
The prevalence of normophosphatemia in non-diabetic and diabetic 
CKD stage 3-5 is 63.04% & 72.97% respectively. 
The prevalence of hyperphosphatemia in non-diabetic and diabetic CKD 
stage 3-5 is 23.91% & 21.62% respectively. 
The difference in phosphorus abnormalities in stage 3-5 diabetic and 
non-diabetic CKD is statistically not significant.  
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BAP: NON-DIABETIC VS DIABETIC: 
Prevalence of abnormal BAP in Diabetic and Non-Diabetic CKD is as 
follows. 
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The prevalence of low BAP in non-diabetic and diabetic CKD stage 3-5 
is 6.52% & 0% respectively. 
The prevalence of normal BAP in non-diabetic and diabetic CKD stage 
3-5 is 74.74% & 78.38% respectively. 
The prevalence of high BAP in non-diabetic and diabetic CKD stage 3-5 
is 21.74% & 21.62% respectively. 
The difference in abnormalities of BAP in stage 3-5 diabetic and non-
diabetic CKD is statistically not significant.  
SYMPTOMS VS BAP: 
Prevalence of abnormal bone turnover marker BAP in symptomatic and 
asymptomatic CKD-MBD patients is as follows. 
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The prevalence of low BAP in asymptomatic and symptomatic MBD in 
CKD stage 3-5 is 4.08% & 2.94% respectively. 
The prevalence of normal BAP in asymptomatic and symptomatic MBD 
in CKD stage 3-5 is 73.47% & 76.47% respectively. 
The prevalence of high BAP in asymptomatic and symptomatic MBD in 
CKD stage 3-5 is 22.45% & 20.59% respectively. 
The difference in Bone turnover marker in stage 3-5 CKD in 
asymptomatic and symptomatic MBD patients is statistically not significant.  
So we infer that symptomatic MBD patients need not have abnormal 
BAP and thus abnormal bone turnover. 
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SYMPTOMS VS MAGNESIUM: 
Prevalence of Magnesium abnormalities in asymptomatic and 
symptomatic CKD-MBD patients is as follows. 
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The prevalence of hypomagnesemia in asymptomatic and symptomatic 
MBD in CKD stage 3-5 is 18.37% & 17.65% respectively. 
The prevalence of normomagnesemia in asymptomatic and symptomatic 
MBD in CKD stage 3-5 is 36.73% & 44.12% respectively. 
The prevalence of hypermagnesemia in asymptomatic and symptomatic 
MBD in CKD stage 3-5 is 48.90% & 38.24% respectively 
The prevalence of magnesium abnormalities in stage 3-5 CKD with 
symptomatic MBD and asymptomatic MBD is not statistically significant. 
DIABETES VS SYMPTOMS: 
 
It is found that there is statistically no difference between the occurrence 
of MBD symptoms in diabetics and non-diabetics. 
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Of the symptomatic patients (n=34), the prevalence of low, normal & 
high BAP is 5.88%, 70.59% & 23.53% in non-diabetics and it is 0%, 82.35% & 
17.65% in diabetics. This difference in diabetic and non-diabetic symptomatic 
individuals is not statistically significant. 
 
In diabetic CKD, the prevalence of abnormal BAP in various stages of 
diabetic retinopathy namely IRMA, NPDR & PDR is compared against normal 
BAP among asymptomatic and symptomatic individuals. This comparison is 
statistically not significant.  
 Page | 67  
 
 
Ophthalmic fundus examination is carried out in 38 patients of the total 
83. In that the prevalence of abnormal BAP is not statistically significant in any 
type of retinopathy encountered. 
CORRELATIONS: 
Correlation between iPTH, BAP and Vitamin D is as follows. 
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              In this scatter plot, Y-axis has Vitamin D values plotted against 
BAP. A Positive correlation is seen between BAP and Vitamin D and it is 
statistically significant. 
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Correlation between iPTH and BAP is seen as follows.  
 
          This picture shows there is a positive correlation between BAP 
and iPTH with a Pearson correlation of 0.34 which is statistically significant. 
Very high values of BAP are associated with very high values of iPTH, 
indicating that those patients might be in high turnover bone disease. 
Correlation between iPTH and calcium is as follows. 
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In this scatter plot, the value of Vitamin D is plotted in Y-axis against 
the values of iPTH in the X-axis. The iPTH and vitamin D are inversely 
correlated but this correlation is not statistically significant. 
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         iPTH and calcium are found to be negatively correlated ie., when 
calcium falls iPTH rises and the reverse occurs in hypercalcemia. The 
parathormone is a minute to minute compensatory response of the body to the 
fall in serum ionized calcium levels. Hence this correlation is strong. 
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DISCUSSION 
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DISCUSSION 
The prevalence of CKD in our Indian population is estimated to be 
between 0.78% and 0.87% 
[78].
 The main purpose of our study is to describe the 
profile of CKD-MBD patients in our hospital. We studied 83 CKD stage 3-5 
patients. The average age of the CKD patients in our study is 54.3 +/- 12.67 
years. Of them 42 were females and 41 males leading to a slight female 
predominance, the M:F ratio is 0.9:1. The symptomatic CKD-MBD individuals 
according to our study comprised 40.96%. Remaining 59.03% didn’t have any 
symptoms related to CKD-MBD. This further reveals how disguising the 
clinical picture of MBD is in our setup.  
The prevalence of hypoparathyroidism is 6.02% indicating the possible 
load of low turnover bone disease, whereas hyperparathyroidism, with a cutoff 
of iPTH >65 pg/ml, is noted in 58.82%  in stage 4 and 87.5% in stage 5, with 
overall 65.06%  indicating high turnover bone disease. Other Indian studies 
show hyperparathyroidism to be 73% 
[80],
 57.3% in stage 4 CKD and 89.5% in 
stage 5 CKD 
[78]
 and 84.62% in stage 4 and 88.29% in stage 5 
[79]. 
High 
turnover state assessed by Z. Jabbar et al is 60% 
[80]
 with a cutoff of iPTH as 
>300pg/ml. In our study 39.7% of patients have a iPTH value of  more than 
two to nine times the normal upper limit out of which 57.6% have high BAP 
indicating the truly high turnover state exists in less than what is actually 
estimated by iPTH. Among those with a possible low turnover disease, diabetic 
and non diabetics are equally affected which is in contrast to previous studies 
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[82]
 which says diabetics are affected more. But neither statement can be 
justified because of the low prevalence of the disease. 
The prevalence of hypocalcemia in our study is noted to be 12%, 
11.76% and 37.5% in stages 3, 4 & 5 respectively.  Study by Agarwal et al 
showed that 29.9% and 49.6% of hypocalcemia is prevalent in stages 4 and 5 
[81].
 
Hyperphosphatemia is found in 4%, 17.65% & 50% in stages 3, 4 & 5 
of CKD with an overall of 22.89% in our study. It is in concordance with other 
Indian studies- Valson et al 59% 
[78],
 Ghosh et al 64.10% in stage 4 and 70.27% 
in stage 5 
[79].
 It can be seen that phosphate retention increases with fall in GFR. 
These are the potential candidates for phosphate lowering therapies if clinically 
feasible. 
Vitamin D deficiency is found only in stages 3 and 4 of CKD, 4% and 
20% namely, in our study. Surprisingly in stage 5 CKD, none of them are 
deficient. Previous studies showed up to 80% of vitamin D deficiency 
[80].
 
Reason for this is not known. Bone biopsy may be able to explain this. 
In our study, various parameters are compared in diabetic and non-
diabetic CKD stage 3-5 patients. None of them showed statistically significant 
difference between the two. This is also in concurrence with previous studies 
[78, 80].
 There is also no difference in the occurrence of symptoms of MBD in 
diabetics and non-diabetics. We also found out that symptomatic patients need 
not have abnormal bone turnover; presence of diabetes is neither associated 
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with the presentation of symptoms, nor associated with an abnormal bone 
turnover.  
Prevalence of an abnormal BAP, in our study, is not found in a 
statistically significant percentage with any of the following ie., symptomatic 
individuals / diabetic individuals / patients with abnormal fundus examination. 
Thus none of the above features in a CKD-MBD patient can predict an 
abnormal bone turnover. Only bone turnover markers next to bone biopsy can 
predict bone turnover diseases in CKD. 
Prevalence of hypomagnesemia in stage 3-5 CKD, in our study shows 
that magnesium is not associated with bone turnover abnormalities.  
In our study, statistically significant correlation, as analyzed by Pearson 
coefficient, is seen between iPTH and calcium (r = -0.30; p = 0.01); iPTH and 
BAP (r = 0.34; p = 0.001); BAP and Vitamin D (r = 0.28; p = 0.01).  
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SUMMARY 
 Symptoms of CKD-MBD need not predict the bone turnover rate 
 There is no statistic difference between diabetic and non-diabetic CKD-MBD. 
 Diabetic Retinopathy need not indicate bone turnover rate. 
 Bone turnover rate is best assessed by turnover markers next only to bone 
biopsy. 
 Hypomagnesemia is not responsible for symptoms of CKD-MBD 
 Vitamin D deficiency is noted in earlier stages of CKD rather than late stages. 
 Clinically quiet nature of this disease tells that early screening is the best way 
to alter the course of the disease.   
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CONCLUSION 
This study concluded that Vitamin D deficiency pattern has changed in 
CKD. Diabetic and Non-diabetic CKD-MBD are not different and hence need 
not be addressed separately. Serum bone marker assay should be included in 
CKD-MBD screening. The screening should begin in the early stage of CKD. 
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LIMITATIONS 
 Extra skeletal calcification was not studied due to lack of Electron Beam 
Computerised Tomography (EBCT) which is the gold standard for this 
parameter. 
 Bone biopsy was not done to confirm the data analysed. 
 The Bio-intact PTH is not compared with BAP in assessing serum bone 
turnover marker. 
 This is a cross-sectional study. True burden of CKD-MBD in the population 
can be assessed in longitudinal studies.  
 National Data about CKD-MBD is not sufficient to correlate at this point of 
time. 
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ANNEXURES 
PROFORMA 
Name:                                                        Age/sex:                                             
Address:                                                       IPNO: 
DM – Yes/No                                      Mobile no: 
Diagnosis: 
Fundus: 
 
QUESTIONNAIRE: 
Proximal Muscle Weakness:                 Yes/No 
Fragile Fracture:                                    Yes/No 
Pruritus:                                                 Yes/No 
Bone Pain:                                             Yes/No 
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INVESTIGATIONS: 
 
Sr. Urea Mg/dl 
Sr. Creatinine Mg/dl 
Sr. Phosphorus Mg/dl 
Sr. Potassium Mg/dl 
Sr. Total calcium Mg/dl 
Sr. Albumin g/dl 
Sr. Corrected calcium Mg/dl 
Sr. Magnesium Mg/dl 
Pl. iPTH Pg/ml 
Pl. Vitamin D Ng/ml 
Sr. BAP U/L 
 
REMARKS: 
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சுயஒப்புதல்  படிவம்  
ஆய்வுசெய்யப்படும்தலைப்பு : நாள்பட்ட சிறுநீரக நநாயில்  
வரக்கூடிய  தாது நற்றும்  எலும்பு   நநாயின்    உருப்஧டிவம்  
 
இடம் :           ப ாது  மருத்துவத்துவ  துரை ,  
                     அரசு  கீழ் ாக்கம்  மருத்துவ  கல்லூாி  
மருத்துவமரை , பென்ரை  
பங்குசபறுபவரின்   சபயர்  :  
பங்குசபறுபவரின்   வயது  :      பங்குசபறுபவரின்   எண்  :  
மநம஬  குறிப்பிட்டுள்஭  நருத்துவ  ஆய்வின்  விவபங்கள்  எ஦க்கு  
வி஭க்கப்஧ட்டது .  ஥ான்  இவ்வாய்வில்  தன்னிச்சைனாக  ஧ங்மகற்கிம஫ன் .  
எந்த  காபணத்தி஦ாம஬ா  எந்த  ைட்டசிக்கலுக்கும்  உட்஧டாநல்  ஥ான்  
இவ்வாய்வில்  இருந்து  வி஬கிக்ககாள்஭ல்஬ாம்  என்றும்  அறிந்து  
ககாண்மடன் .  
இந்த  ஆய்வு  ைம்஧ந்தநாகமவா ,   இசத  ைார்ந்து  மநலும்  ஆய்வு  
மநற்ககாள்ளும்ம஧ாதும்  இந்த  ஆய்வில்஧ங்கு  க஧றும்  நருத்துவர்  
என்னுசடன  நருத்துவ  அறிக்சககச஭  ஧ார்ப்஧தற்கு  என்  அனுநதி  
மதசவயில்ச஬  எ஦  அறிந்து  ககாள்கிம஫ன் .   இந்த  ஆய்வின்  மூ஬ம்  
கிசடக்கும்  தகவச஬மனா ,  முடிசவமனா  ஧னன்஧டுத்திக்ககாள்஭  நறுக்க  
நாட்மடன் .  
இந்த  ஆய்வில்  ஧ங்கு  ககாள்஭  ஒப்புக்ககாள்கிம஫ன் .    இந்த  
ஆய்சவ  மநற்ககாள்ளும்  நருத்துவ  அணிக்கு  உண்சநயுடன்  இருப்ம஧ன்  
என்றும்  உறுதினளிக்கிம஫ன் .  
 
 
஧ங்மகற்஧வரின்    சககனாப்஧ம்                     ஆய்வா஭ரின்  சககனாப்஧ம்  
இடம்  :  
மததி  :  
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SL 
NO 
NAME 
AG
E(Y
RS) 
SE
X 
URE
A 
mg/dl 
CREAT
ININE 
mg/dl 
eGFR 
ml/min/1.
73m2 
CALCI
UM 
mg/dl 
ALBU
MIN 
g/dl 
CORRECT
ED 
CALCIUM 
mg/dl 
POTASS
IUM 
mg/dl 
MAGN
ESIUM 
mg/dl 
PHOSP
HORUS 
mg/dl 
iPTH 
pg/ml 
VIT-D 
ng/ml 
BAP 
U/L 
DI
AB
ET
ES 
SY
M
PT
O
M
S 
FUNDUS 
1 Kasthuri 60 F 196 18.9 2 7.6 3 8.4 5.4 2.3 7.1 502.6 15 39.6 N N ND 
2 Arul 37 M 179 15.5 3 5.9 3.7 6.1 5 2.3 7.9 577 9.8 42 N Y HTR-2 
3 Ramya 25 F 185 13 4 8 3.3 8.5 4.1 1.5 6.4 656.9 9.8 32.5 N N ND 
4 Pandiyan 48 M 162 10.7 5 8.2 4.8 7.5 3.9 2.7 6.6 198.7 25.8 17.6 N N NORMAL 
5 Velu 62 M 104 8.6 6 9.6 3.8 9.7 5 1.4 5.1 501.6 25.9 27.1 N N HTR-1 
6 Jothy 61 F 114 6.7 6 6.9 3.4 7.3 4.4 1.6 3.9 322.1 4.2 52.1 Y N NPDR 
7 
Selvam 55 F 151 7.2 6 8.6 3.9 8.6 4.5 1.4 6.7 893.6 18.7 
143.
8 
Y Y NPDR 
8 Venda 57 F 144 6.8 6 8.8 3.4 9.2 6 1.8 5.7 240.4 15.8 29.8 Y Y PDR 
9 Vijay Kumar 40 M 158 7.9 8 8.8 2.7 9.8 5.4 3.9 10.5 172.7 16.5 25.2 N Y ND 
10 
Kathayee 55 F 136 5.3 8 9.5 4.1 9.4 5.9 0.3 5.2 768.4 18.8 
147.
5 
N Y ND 
11 Ramalingam 65 M 96 6.3 8 8.8 3.7 9 4.3 4.2 3.8 256.3 13.4 41.1 Y Y NPDR 
12 
Vincent 46 M 112 6.7 9 8.8 4.1 8.7 4.3 1 4.5 295 12.4 21.1 Y N 
NPDR,BR
VO 
13 Anandhan 34 M 143 6.6 10 8.9 3.3 9.4 4.3 2 4.2 91.9 10 9.1 N N HTR-3 
14 Saraswathi 38 F 53 5.3 10 7.5 2.1 9 2.6 2.5 3.9 43.3 6.8 43.8 N N NORMAL 
15 Sethuraman 62 M 174 5.6 10 9.6 4.2 9.4 5.3 1.2 5.2 133.4 12.9 18.9 Y N ND 
16 Malar 55 F 97 4.5 10 9 3.5 9.4 5 2.3 3.4 179.1 7.2 50 Y N NPDR 
17 Kandhamani 69 F 85 4.1 10 8.9 3.7 9.1 3.8 4.8 3.6 183.1 18.5 20.5 Y Y NPDR 
18 Elumalai 60 M 158 5.5 10 4.1 2.9 4.9 5.6 1.8 5.4 5.9 29.7 29.5 Y Y ND 
19 Parvathy 65 F 86 4.2 10 9.1 3.4 9.5 5.4 1.6 3.7 30.9 9.1 17.4 Y Y NORMAL 
20 Kuppammal 65 F 118 3.9 11 8.1 3.6 8.4 3.6 2.8 3.6 235.4 8.9 41.8 Y N NPDR 
21 Selvi 52 F 91 4 12 10.1 3.8 10.2 5 3.6 4.5 285.2 10.5 28.9 N N CRVO 
22 Nagesh 50 M 78 4.6 14 9.2 4.3 8.9 4.4 4.1 2.6 179.1 15.6 41 Y N ND 
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23 Abdul Ameen 60 M 89 4.3 14 9.9 3.9 9.9 4.7 2.2 3.9 94.8 7.8 19.1 Y Y NPDR 
24 Leelavathy 38 F 90 3.9 14 8.5 2.7 9.5 3.1 2.7 5.2 70.1 14.1 21 Y Y ND 
25 Vasantha 49 F 103 3.4 15 9.7 4.1 9.6 5.7 1.6 4.4 90.1 13.9 16.9 N N ND 
26 Janakiraman 50 M 60 4.4 15 9.2 4.6 8.7 5.1 1.7 3.9 62.8 30.7 49.1 N N ND 
27 Jamuna 24 F 97 3.7 16 9.5 4.3 9.2 3.3 2.1 3.7 443.8 18.9 31.9 N N ND 
28 Valliyammal 60 F 65 3.1 16 8.5 3.9 8.5 4.9 2.7 4.6 117.2 19.7 28.7 N N ND 
29 Sethuraman 64 M 104 3.7 16 8.3 3.7 8.5 5.4 3.9 2.6 67.6 11.4 18.3 Y Y ND 
30 
Arumugam 54 M 59 3.8 17 9.4 4.4 9 3 1.5 2.3 134.9 38.3 
194.
7 
N N ND 
31 Srinivasan 55 M 95 3.8 17 8.7 5.1 7.8 4.8 0.7 5.6 415.1 25.3 36.6 N Y RP 
32 Kondaiyan 85 M 70 3 18 9.2 4.3 8.9 4.7 1.5 4.9 137.2 17.2 70.8 N Y ND 
33 Fathima Beevi 48 F 52 3 18 9.1 3.5 9.5 4 3.7 4.4 30.3 22.9 13.2 Y Y NPDR 
34 
Chinnaiyah 52 M 116 3.5 19 7.5 3.7 7.7 3.4 4.5 3.2 632 18.2 
146.
7 
N N ND 
35 Balaraman 48 M 106 3.4 20 8.8 3.6 9.1 4.2 2.9 3.9 258.8 9.4 66.8 N N ND 
36 Suppammal 65 F 48 2.5 20 8.9 4.4 8.5 5 2.1 2.9 53.9 8.6 69.3 Y N ND 
37 Srinivasan 62 M 74 3 21 8.4 3.9 8.4 2.8 3 3.8 108 14.8 19.6 Y N NPDR 
38 Rani 55 F 54 2.5 21 9.9 4.4 9.5 4.7 6.2 3.6 49.4 28 16.6 Y Y ND 
39 Boomiyammal 65 F 67 2.3 22 10.7 3.6 11 2.8 1.1 4 12.1 21.1 20.3 N Y ND 
40 Sundaramoorth
y 
47 M 105 3.1 23 8.7 3.6 9 4.1 0.8 5.1 121.6 7.1 58.2 Y N PDR 
41 Kalaichelvi 50 F 65 2.7 23 8.8 3.2 9.4 5.9 1.9 4 45.3 39.4 32.8 Y Y NPDR 
42 Kamala Glori 70 F 68 2.1 23 9.5 4.5 9.2 5.3 1.8 4.8 44.8 15.1 34.6 Y Y NORMAL 
43 Jayaraman 72 M 72 2.6 24 9.3 4 9.3 3 2.2 3.9 66.2 50.1 27 N N ND 
44 Jayalakshmi 55 F 109 2.5 24 9.7 4.6 9.2 4.5 3.7 4.2 163.8 27.8 24.8 Y N ND 
45 Kannammal 75 F 62 1.9 25 9.1 3.8 9.2 3.8 6.8 5.1 125.9 50.7 19.3 N Y ND 
46 Ramaniyammal 55 F 66 2.1 26 10.5 3.9 10.5 3.8 1.7 2.8 69.1 18.1 27.7 N N ND 
47 Vedachalam 59 M 30 2.6 26 10.5 5 9.7 3.9 1.7 2.1 39.6 14.7 24.3 N Y ND 
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48 Saraswathy 73 F 54 1.8 27 8.6 3.6 8.9 4.3 2.1 3.6 55.2 6.6 22.3 N N NORMAL 
49 Dharmalingam 57 M 151 2.5 27 9.9 3.9 9.9 4.3 0.2 4.5 78.6 31.8 30.7 N Y ND 
50 Premkumar 66 M 59 2.4 27 9.6 4.6 9.1 5.3 2.8 3.8 57.7 20.5 64.4 Y N ND 
51 Usha 58 F 75 2 27 9.4 4.5 9 6.1 2 4.5 45.5 16.2 39.8 Y N NPDR 
52 Gunalan 52 M 40 2.5 28 9.5 4.4 9.1 4.8 3.3 3.2 36.8 21.1 21 N Y ND 
53 Rajasekaran 75 M 47 2.2 28 8.9 4.2 8.7 4.2 2.4 3.1 80.6 18.9 27.6 Y N NPDR 
54 Sulochana 68 F 50 1.8 28 9.5 4.2 9.3 4.9 0.9 3.7 49.3 16.6 35.1 Y N NORMAL 
55 Akilunisha 50 F 41 2 28 9.3 4.6 8.8 5 1.8 3 105.2 15.8 45.8 Y Y NORMAL 
56 Palaniammal 55 F 28 1.9 29 9.4 4 9.4 5.1 1.9 2.9 67.9 21.6 13.5 N N NORMAL 
57 Suriyaprakasam 62 M 44 2.3 29 9.4 4 9.4 3 0.4 3.1 105.8 6.9 37.5 Y N ND 
58 Ranganathan 47 M 46 2 29 9.1 3.7 9.3 5.7 1.8 2.4 30.5 46.7 301 Y Y NORMAL 
59 Devaraja 58 M 38 2.3 30 10 5.2 9 2.9 2 2.8 64.4 17.4 28 Y Y NPDR 
60 Muthu 49 M 52 2.4 31 9.1 4.1 9 2.1 2.4 3.3 119.2 13.3 32.6 N N ND 
61 Ponnurangan 68 M 47 2.1 31 9.1 4.1 9 4.2 2.7 4 145.5 18.2 31.2 N N ND 
62 Kasiyammal 65 F 90 1.7 31 8.7 3.8 8.8 6.7 1.9 4.3 134.3 9.9 45.7 N Y ND 
63 Samuvel 40 M 93 2.5 31 8.8 3.2 9.4 3.5 2.7 3.8 69.1 10.7 18.8 Y N NPDR 
64 Ramadevi 54 F 84 1.8 31 9.4 4.8 8.7 5.4 5 3.4 53.3 16.6 38.8 Y N NORMAL 
65 Nirmala 45 F 65 1.8 33 8.5 4 8.5 5.1 2.3 3.8 135.5 6.5 28.7 N Y ND 
66 Indira 45 F 57 1.8 33 9.9 4.8 9.2 4.2 6.2 2.8 31.7 18.3 20.5 N Y ND 
67 
Latha 46 F 38 1.8 33 10.2 4 10.2 4 4.2 3.8 163.8 7.4 
28.7
2 
Y N IRMA 
68 Shivakumar 48 M 63 2.2 34 10.3 4.4 9.9 4.4 3.5 3.9 41.5 18.6 17.5 N N ND 
69 Rajendiran 57 M 39 2.1 34 9.3 3.9 9.3 5.2 2.1 3.4 79.1 25.7 22.3 N Y ND 
70 Diwakar 18 M 59 2.5 36 9.3 4.5 8.9 2.9 3.4 2.8 88.3 27.1 35.1 N N NORMAL 
71 Lakshmi 40 F 59 1.7 37 10.1 5 9.3 3.9 3.1 3.4 93.9 10.8 22.6 N Y ND 
72 Meena 55 F 56 1.5 39 9.7 4.4 9.3 4.3 1.1 3.6 96.5 11.7 23.1 N N ND 
73 Shanthi 40 F 102 1.6 40 9.9 3.8 10 5 1.4 5.7 11.6 18.9 14.9 Y N NORMAL 
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Urea mg/dl 15-45 iPTH 
pg/ml 
15-65 eGFR stage 5 <15 
 
stage 4=15-29 
stage 3b=30-44 
stage 3a=45-59 
  
  
 
Creatinine 
md/dl 
F=0.5-0.9 
M=0.7-1.2 
Vitamin  D 
ng/ml 
<30 
ng/ml=deficiency  
Calcium 
mg/dl  
8.6-10 mg/dl BAP u/l F= 11.6-29.6 
M=15-41.3  
Phosphorus 
mg/dl 
2.5-4.5  Magnesium 
Mg/dl 
1.5-2.3  
 
  
  
   
74 Devi 25 F 41 1.7 41 9.8 4.4 9.4 4.4 5.1 2.9 8.35 12.3 26.9 N N NORMAL 
75 Hari prasad 35 M 63 1.9 45 9.3 3.6 9.6 4 4 2.4 12 9.7 22 N N ND 
76 Vijayan 54 M 49 1.7 45 7.6 1.9 9.2 4 1.9 2.9 51.1 5.8 19.6 N N ND 
77 Venugopal 70 M 24 1.5 46 9.8 4.6 9.3 4.4 1.1 3.2 21.8 24.6 18.3 N N NORMAL 
78 Sivaraman 48 M 31 1.7 47 9.3 4.7 8.7 3.6 1.8 2.4 98.1 8.1 45.8 N N ND 
79 Masilamani 80 M 48 1.4 47 9.6 3.8 9.7 5.2 2.7 4 36.5 41.5 13.9 N Y ND 
80 Vishwanathan 53 M 28 1.6 48 9.1 3.8 9.2 4.5 1.7 1.9 18.7 14.3 16 Y N NPDR 
81 Vanaja 48 F 61 1.2 53 8.5 3.8 8.6 3.1 4.1 2.2 103.3 8.2 12 N N ND 
82 Boologam 65 F 38 1.1 53 10 4.5 9.6 4.1 2.7 3.5 31.1 16.5 23.8 Y Y ND 
83 Govidammal 60 F 39 1.1 55 8.9 3.8 9 4.3 0.1 2.1 154.2 3 19.5 N Y ND 
